drugset
drugset / Trial / NCT05351047

A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry

NCT05351047 ↗

Phase 1 Completed 24 enrolled AstraZeneca Parexel · collab
RandomizedSequentialDouble-blindTreatment

Summary

This is a Phase 1 study to assess the the safety, tolerability and pharmacokinetics (PK) of AZD2373, following subcutaneous (SC) administration of multiple ascending doses (MAD) of AZD2373 in healthy male participants of sub-Saharan West African ancestry.

Timeline

Start
2022-04-04
Primary completion
2023-07-06
Completion
2023-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Opemalirsen Unknown — Subcutaneous

Indications

No indication recorded.